An observational study in Ischemic Stroke, sponsored by Shouchun Wang, MD, PhD. Recruiting at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-03.
Sponsored by Shouchun Wang, MD, PhD · Observational
The objective of this study was to evaluate the safety and efficacy of early submaximal balloon angioplasty combined with medical therapy vs medical therapy alone for minor stroke/transient ischemic attack with intracranial atherosclerosis etiology.
In this study, 416 patients with minor strokes or transient ischemic attacks due to symptomatic intracranial atherosclerotic stenosis within one week of the onset of last ischemic symptoms from 20 centers in China were enrolled. The observation group received early submaximal balloon angioplasty, while the control group received only medical therapy. Two groups will be followed up for 1 year to evaluate the safety and efficacy of early submaximal balloon angioplasty combined with medical therapy vs medical therapy alone for minor stroke / transient ischemic attack with intracranial atherosclerosis etiology.
7,283 studies on the registry are indexed under Stroke; 2,013 are open to participants now.
This study's planned enrollment of 416 is above the median of 160 across 1,692 observational studies indexed under Stroke.
Browse Stroke studies →This is the only study on the registry with Shouchun Wang, MD, PhD as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients with minor stroke/transient ischemic attack.
Exclusion Criteria:
The observation group received early submaximal balloon angioplasty and medical therapy.
Procedure: Submaximal balloon angioplasty
The control group received only medical therapy.
The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
Stroke or death within 30 days or ischemic stroke in the culprit artery territory from 30 days to 1 year
Stroke or death within 30 days or ischemic stroke in the culprit artery territory from 30 days to 1 year
Time frame: 30 days, 1 year
Stroke or death within 30 days after enrollment
Stroke or death within 30 days after enrollment
Time frame: 30 days
Ischemic stroke in the territory of criminal artery from 30 days to 1 year after enrollment
Ischemic stroke in the territory of criminal artery from 30 days to 1 year after enrollment
Time frame: 1 year
Restenosis rate of criminal artery within 1 year after enrollment
Restenosis rate of criminal artery within 1 year after enrollment
Time frame: 1 year
Evaluation of neurological function improvement within 90 days of enrollment
Evaluation of neurological function improvement within 90 days of enrollment
Time frame: 90 days
Intracranial hemorrhage within 30 days of enrollment
Intracranial hemorrhage within 30 days of enrollment
Time frame: 30 days
Complications associated with endovascular therapy
Complications associated with endovascular therapy
Time frame: 24 hours, discharge, 30 days, 90 days, and 1 year after enrollment
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.